

## Mutation of an L-Type Calcium Channel Gene Leads to a Novel Human Primary Cellular Immunodeficiency

**Authors:** Franz Fenninger<sup>1,2,3,4,5</sup>, Shawna R. Stanwood<sup>1,2,3,4,5</sup>, Chieh-Ju Lu<sup>1,3,4,5</sup>, Cheryl G. Pfeifer<sup>1,3,4,5</sup>, Sarah E. Henrickson<sup>9,10</sup>, Omar Khan<sup>10, 11</sup>, Kaitlin C. O'Boyle<sup>10, 11</sup>, Kelly Maurer<sup>9</sup>, Melanie Ruffner<sup>9</sup>, Ramin S. Herati<sup>10</sup>, Neil D. Romberg<sup>9</sup>, E. John Wherry<sup>10,11</sup>, Kathleen E. Sullivan<sup>9</sup>, Wilfred A. Jefferies<sup>1,2,3,4,5,6,7,8\*</sup>

### Affiliations:

<sup>1</sup>Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada

<sup>2</sup>Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada

<sup>3</sup>Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

<sup>4</sup>Centre for Blood Research, University of British Columbia, Vancouver, BC, Canada

<sup>5</sup>The Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada

<sup>6</sup>Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

<sup>7</sup>Department of Zoology, University of British Columbia, Vancouver, BC, Canada

<sup>8</sup>Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

<sup>9</sup>Division of Allergy Immunology at The Children's Hospital of Philadelphia, Philadelphia, PA, USA

<sup>10</sup>Institute for Immunology, University of Pennsylvania, Philadelphia, PA, USA

<sup>11</sup>Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA

\*Correspondence to: wilf@msl.ubc.ca

**Conflict of Interest:** WAJ declares funding from Pascal Biosciences Inc.

**Abstract:** Human primary immunodeficiencies are inherited diseases that can provide valuable insight into the immune system. Calcium ( $\text{Ca}^{2+}$ ) is a vital secondary messenger in T lymphocytes regulating a vast array of important events including maturation, homeostasis, activation, and apoptosis and can enter the cell through CRAC, TRP, and Cav channels. Here we describe three Cav1.4-deficient siblings presenting with X-linked incomplete congenital stationary night blindness as well as an immune phenotype characterized by several recurrent infections. Complete exome sequencing demonstrated that the patients share only a single pathogenic allele; a R625X (p.Arg625Ter) point mutation that leads to a premature stop codon in the *CACNA1F* gene encoding the L-type  $\text{Ca}^{2+}$  channel Cav1.4. The subjects uniformly exhibited an expansion of central and effector memory T lymphocytes, and evidence of T lymphocytes exhaustion with corresponding upregulation of inhibitory receptors. Moreover, the sustained elevated levels of activation markers on B lymphocytes suggest that they are in a chronic state of activation. Finally, the T lymphocytes from patients and *CACNA1F* knockdown Jurkat T lymphocytes exhibited a reduced  $\text{Ca}^{2+}$  flux, compared to controls. This is the first example where the mutation of any Cav channel causes a primary immunodeficiency in humans and establishes the physiological importance of Cav channels in the human immune system.

## Introduction

Human primary immunodeficiencies (PIPs) are rare familial diseases that can be caused by a mutation in a variety of genes that affect the immune system, with currently 354 characterized monogenic forms (1). PIPs can affect the innate and adaptive arms of the immune system. Chronic granulomatous disease for example leaves phagocytes unable to produce microbicidal oxygen radicals, therefore severely compromising the innate immune system. PIPs that affect adaptive immunity usually exhibit functional defects of T and/or B lymphocytes as well as natural killer (NK) cells (2). Mutation in the genes *ZAP-70* and *LAT* for example lead to persistent infections that can be life-threatening due to defective T cell signaling. Some PIPs can be attributed to deficiencies in calcium ( $\text{Ca}^{2+}$ ) signaling (1).  $\text{Ca}^{2+}$  is a vital signaling molecule in all cells including immune cells and controls important processes like differentiation, homeostasis, activation, proliferation, and apoptosis (3). In lymphocytes, crosslinking the antigen receptor activates a signaling cascade that eventually leads to  $\text{Ca}^{2+}$  release from the endoplasmic reticulum (ER) into the cytoplasm (4). Upon  $\text{Ca}^{2+}$  depletion of the ER,  $\text{Ca}^{2+}$  channels in the plasma membrane open and a  $\text{Ca}^{2+}$  influx from the extracellular space is triggered. This process is called store-operated  $\text{Ca}^{2+}$  entry (SOCE) and the main plasma membrane channel involved in it is coined  $\text{Ca}^{2+}$  release-activated  $\text{Ca}^{2+}$  (CRAC) channel (5). The CRAC channel consists of the pore-forming unit called ORAI1 and a  $\text{Ca}^{2+}$  sensing protein named STIM1 that detects low levels of  $\text{Ca}^{2+}$  in the ER to activate the channel. Loss-of-function mutations in *ORAI1* or *STIM1* genes result in the partial abrogation of SOCE and defective T cell activation (6–9).

Apart from the CRAC channel however, there exist numerous other  $\text{Ca}^{2+}$  channels in the plasma membrane of lymphocytes that also contribute to the antigen receptor-mediated flux. Among them

are the voltage-dependent  $\text{Ca}^{2+}$  channels (VDCCs), which have emerged as important players in immune cells (4). VDCCs consist of the pore-forming Cav ( $\alpha 1$ )-, the  $\beta$  regulatory-, and several other auxiliary subunits. They have been grouped into different families including the L-type  $\text{Ca}^{2+}$  channels, which are further divided into Cav1.1, 1.2, 1.3, and 1.4 (10). Since they are traditionally activated by a change in membrane potential, these channels have primarily been described in electrically excitable cells but more recent studies have also demonstrated that L-type  $\text{Ca}^{2+}$  channels play critical roles in murine and human leukocytes (10,11). Our lab has previously shown that Cav1.4 mRNA is subject to extensive splicing, including unique spliceforms in T lymphocytes resulting in the excision of the membrane-associated voltage sensor region resulting in the Cav1.4 channel becoming ligand gated (12). In another study with knock-out mice deficient in Cav1.4 our lab demonstrated that Cav1.4 plays an important role in T lymphocyte homeostasis and activation in mice. Specifically, Cav1.4 was required for the survival of naïve T lymphocytes as well as pathogen-specific T cell responses (13). Cav1.4, whose  $\alpha 1$  subunit is encoded by the gene *CACNA1F* on the X chromosome, is also expressed in human T lymphocytes, which led us to hypothesize that it might be important for T cell function in humans as well (12,14).

For humans, the function of Cav1.4 is well described in the eye as its absence or reduced function can lead to incomplete congenital stationary night blindness (CSNB) (15). However, the role of Cav1.4 in the human immune system remains elusive. We had the opportunity to examine three brothers, each harboring the same *CACNA1F* mutation leading to incomplete CSNB, who we determined uniformly exhibit a PID. Here we describe the effect of Cav1.4 deficiency in human lymphocytes and mechanisms underlying a new X-linked immunological disorder.

## Results

### *Case presentation*

Three male siblings (16 – 20 years old) who each harbor the same mutation in the *CACNA1F* gene and who each present with immune deficiencies in addition to incomplete CSNB were studied. Their immune deficiencies include frequent recurrent infections, particularly of the ear and upper respiratory tract, tolerance defects, as seen by antinuclear antibodies in their serum (titer 1:160 for patient 1, 1:80 for patient 2, speckled). Other symptoms including aphthous ulcers, fatigue, muscle weakness, joint hypermobility, intermittent creatine phosphokinase (CPK) abnormalities, postural orthostatic tachycardia syndrome, Ehlers-Danlos syndrome and rashes were reported. A comprehensive list with all the patients' conditions according to their mother can be found in **Table S1**. A complete blood count with differential did not show any dramatic deviations from the normal ranges (**Table S2**). In previous clinical flow cytometric tests, it was found that one sibling exhibits a CD4/CD8 T cell ratio lower than the reference range while his brothers also had a ratio at the low end of the range. Additionally, two of the three siblings displayed a below normal frequency of naïve CD4+/CD45RA+ T cells (**Table S3**). Furthermore, two of the three siblings exhibited impaired responses to Tetanus, Pokeweed mitogen, and Candida, while responses to PHA and ConA were normal (**Table S4**). Finally, a high viral load of EBV and antibodies against EBV were detected in two of the three siblings (**Table S5**, third sibling not tested).

### *Patients harbour R625X mutation in CACNA1F gene*

The siblings as well as their mother underwent several genetic tests including Whole Exome Sequence Analysis by GeneDX (XomeDxPlus). In this analysis a R625X (p.Arg625Ter) point mutation that leads to a premature stop codon in the *CACNA1F* gene was discovered. The amino

acid substitution is caused by the 1873C>T (NM\_005183.3) nucleotide mutation changing the codon CGA to TGA in exon 14 in the voltage sensing domain of the protein (**Fig. 1A**). The dbSNP identifier is rs886039559 and the surrounding DNA sequence is

GCAGCCCTTGGGCATCTCAGTGCTC[C/T]GATGTGTGCGCCTCAGGATCTT. The R625X variant was previously described in a family with incomplete CSNB (16) and is predicted to cause loss of normal protein function due to protein truncation or nonsense-mediated mRNA decay. It was not observed in the approximately 6503 individuals in the NHLBI Exome Sequencing Project nor in the 60706 unrelated individuals in the ExAC database.

This variant is present in all three siblings who inherited the mutated allele from their mother who is a heterozygous carrier. Since *CACNA1F* is encoded on the X chromosome, the siblings are all hemizygous for the mutation. On the maternal side of the family there are two additional males who are also affected by CSNB and females including the siblings' mother exhibit autoimmune defects. While their mother has been tested heterozygous for the R625X mutation the other individuals displaying CSNB and autoimmune defects are assumed carriers of the mutated allele (**Fig. 1B**).

The youngest of the three siblings is also hemizygous for the missense V40M variant in the *SH2D1A* gene (dbSNP rs199639961), which however did not change the expression of the encoded protein SAP on T and NK cells and is therefore not considered to be pathogenic. The middle sibling is homozygous and the oldest heterozygous for the Q45X (dbSNP rs17602729) and P81L (dbSNP rs61752479) variants in the *AMPD* gene. These *AMPD* variants have a high allele frequency and are only pathogenic in rare cases. The patients had other benign SNPs in genes *MEFV*, *NLRP3*, *TNFRSF1A* (rs224225, rs224224, rs224223, rs224213, rs224208, rs224207, rs224206, rs1231122, rs3806268, rs767455, rs1800693, rs12426675). An overview of the genetic

variants identified by GeneDx can be found in **Table S6**. The pathology in the three male patients is inherited as an X-linked genetic disease. The R625X mutation in *CACNA1F* is the only common pathogenic genetic alteration present in all three siblings. We therefore conclude that the R625X mutation in *CACNA1F* causes their immune dysfunction.

#### ***Cav1.4 deficiency leads to a reduced CD4/CD8 T cell ratio***

In order to further explore the role of Cav1.4 in humans, we isolated PBMCs from whole blood of these patients as well as several age- and sex-matched control donors. We analyzed the patients' T cell populations by flow cytometry and could confirm the decreased CD4/CD8 T cell ratio found in previous clinical tests. This was due to a reduced frequency of CD4 T cells, which was compensated by an increase of CD4- CD8- double negative cells. The frequency of CD8 T cells and B cells (CD19+) was comparable to control donors (**Fig. 2A**).

#### ***Cav1.4-deficient patients exhibit an increased frequency of memory and regulatory T cells***

We next examined naïve and memory T cell subsets in these patients to assess to which specific population the reduced frequency of CD4 T cells can be attributed. In humans, naïve T cells are generally CD62L+, CCR7+, CD27+, CD45RA+, CD45RO-, central memory T cells ( $T_{CM}$ ) are CD62L+, CCR7+, CD27+, CD45RA-, CD45RO+, effector memory T cells ( $T_{EM}$ ) are CD62L-, CCR7-, CD27-, CD45RA-, CD45RO+ and end-stage effector T cells ( $T_{Eff}$ ) are CD62L-, CCR7-, CD27-, CD45RA+, CD45RO- (17,18). For this experiment, we used flow cytometry markers to group the cells into naïve (CD62L+ CD45RO-),  $T_{CM}$  (CD62L+ CD45RO+),  $T_{EM}$  (CD62L- CD45RO+), and end-stage  $T_{Eff}$  cells (CD62L- CD45RO-) (**Fig. 2B**). Compared to healthy control donors, the patients had a higher frequency of CD8  $T_{CM}$  cells as well as an increased frequency of

$T_{EM}$  cells, which was more pronounced in the CD8 T cell subset. While their naïve CD8 T cell frequency was normal, the naïve CD4 T cell frequency was reduced (in agreement with previous clinical tests), which is the main reason for the reduced frequency of total CD4 T cells (**Fig. 2C**). Lastly, the patients also exhibited a significantly increased frequency of regulatory T lymphocytes as well as CD8 MAIT cells (**Fig. S1A/B**). The frequency of T lymphocytes expressing a  $\gamma\delta$  TCR was similar in patients and controls (**Fig. S1C**).

### ***T cells of Cav1.4-deficient patients have multiple upregulated inhibitory receptors***

Next, we looked at the activation and exhaustion status of the patients' T cells. T cell exhaustion develops during chronic infections as well as cancers and leads to poor effector function (19). Affected T cells can be identified by the continuous high expression levels of inhibitory receptors (IRs) like PD-1, CTLA-4, and TIGIT (17). Patients' memory T and  $T_{Eff}$  cells of both the CD4 and CD8 subsets exhibited increased levels of PD-1 on their cell surface as seen by flow cytometry (**Fig. 3A**).  $T_{CM}$  cells and the CD4+  $T_{EM}$  subset were especially affected. The patients' PBMCs were also analyzed using CyTOF. Apart from confirming the expansion of  $T_{CM}$  and  $T_{EM}$  cells (not shown), we also observed the upregulation of multiple IRs that are consistent with CD8 T cell exhaustion. Apart from PD-1, other IRs including TIGIT and the transcription factors T-bet and EOMES, which are characteristic for exhausted T cells (20), were also significantly upregulated on the patients' CD8 T cells. There was a significant increase in EOMES+ PD-1+ cells, which represent terminally differentiated exhausted T cells, that are known to have very limited proliferation and cytokine production potential (21) (**Fig. 3B**).

### ***B lymphocytes of Cav1.4-deficient patients are chronically activated***

B lymphocytes are activated by binding to an antigen with their BCR. In T lymphocyte-dependent responses, they additionally bind to CD40L, expressed on T helper lymphocytes, which together with secreted cytokines like IL-4 and IL-21 provides a costimulatory signal for the B lymphocytes (22). Throughout this process, B lymphocytes upregulate several activation markers on their cell surface, including MHCII. B cells (CD19+) of the patients expressed high levels of the MHCII isotype HLA-DR (**Fig. 3C**), implying that they are in an activated state. Also, the expression levels of the adhesion molecule CD62L, which is shed upon B lymphocyte activation, were strongly reduced on the surface of the patients' B lymphocytes. Additionally, the patients exhibited a higher frequency of class-switched B cells (**Fig. S1D**).

### ***Cav1.4 deficiency impairs Ca<sup>2+</sup> flux in T lymphocytes but not B lymphocytes***

We next performed a Ca<sup>2+</sup> flux assay using the patients' PBMCs. PBMCs were labeled with Ca<sup>2+</sup> dyes and different lymphocyte markers, stimulated with thapsigargin, and the Ca<sup>2+</sup> flux was recorded by flow cytometry. While B lymphocytes of the patients displayed a normal flux, the Ca<sup>2+</sup> mobilization in their CD8 and CD4 T lymphocytes was reduced, compared to healthy donor cells (**Fig. 4**). Thapsigargin blocks the reuptake of Ca<sup>2+</sup> into the ER, which triggers SOCE without engaging the antigen receptor and the associated proximal TCR/BCR signaling pathway. We therefore hypothesize that Cav1.4 is also involved during SOCE and that its absence leads to a reduction of the induced Ca<sup>2+</sup> flux. Interestingly, stimulation with  $\alpha$ -CD3 triggered a similar Ca<sup>2+</sup> flux in CD4 and CD8 T cells of Cav1.4-deficient patients and healthy controls (not shown). We also tested whether the shRNA-mediated knockdown of Cav1.4 in Jurkat T cells reduced the TCR-

induced  $\text{Ca}^{2+}$  flux. The shRNA treated cells, which exhibited an 80% reduction of *Cacna1f*mRNA, demonstrated a reduced  $\text{Ca}^{2+}$  flux upon  $\alpha$ -CD3 stimulation (**Fig. S2**).

#### ***Cytokine secretion in Cav1.4-deficient T lymphocytes is comparable to healthy donor levels***

Lastly, to evaluate T lymphocyte function, we stimulated PBMCs with  $\alpha$ -CD3 and  $\alpha$ -CD28/49d and then quantified the expression of the T lymphocyte activation marker CD38 as well as the intracellular cytokine levels of IFN- $\gamma$  and IL-2. Contrary to our expectations they were upregulated similarly in patients' and controls' non-naive T lymphocytes (gated by excluding CD27+ CD45RA+) (**Fig. S3**). In fact, the patients' T lymphocytes had an increased frequency of CD38+ T lymphocytes compared to the controls after stimulation. However, it is important to note that the presence of exhaustion does not preclude the potential to secrete cytokines. In comparison to mouse studies, which are generally based on comparison of the activation state and function of antigen specific lymphocytes in a specific infection, in human studies we are often unable to focus on an antigen specific sub-population for appropriate comparison of functional capacity between affected and control subjects.

## Discussion

We have characterized the first example of a mutated Cav channel causing a primary immunodeficiency in humans, which is inherited as an X-linked genetic disease. The patients we examined have an R625X point mutation that leads to a premature stop codon in their *CACNA1F* gene. No other pathogenic SNPs exist in any of the patients. Thus, the R625X mutation in *CACNA1F* is the only common pathogenic genetic alteration present in all three siblings. We therefore concluded that the R625X mutation in *CACNA1F* causes their immune dysfunction. Many mutations in *CACNA1F*, including this one, have been linked to CSNB (16). The patients in the present study also exhibit this phenotype and participated in a study further describing their disease (23). This, however, is the first report of an immune disorder caused by a mutation in the *CACNA1F* gene, and appears to be a novel phenotype amongst all human primary immunodeficiencies.

The siblings exhibit a low CD4 T lymphocyte frequency and hence a low CD4/CD8 T lymphocyte ratio and also present a high frequency of dysfunctional T lymphocytes and an expansion of memory T lymphocytes. Additionally, the frequencies of regulator T lymphocytes as well as CD8 MAIT lymphocytes are significantly elevated in the siblings. The B lymphocytes of Cav1.4-deficient patients were chronically activated, as indicated by the upregulation of several activation markers. Interestingly, the human *CACNA1F*-/- B lymphocytes also exhibited a loss of CD62L. CD62L is an adhesion molecule that is necessary for cell migration to the site of inflammation and does so by mediating the rolling of leukocytes on the endothelium. It was found that the P2X7 receptor agonist benzoyl-benzoyl-ATP induces shedding of CD62L on lymphocytes (24). As P2X receptors also flux  $\text{Ca}^{2+}$  across the plasma membrane of lymphocytes, this implies a potential role

of  $\text{Ca}^{2+}$  in the shedding of CD62L. Interestingly, phorbol 12-myristate 13-acetate, a strong B cell activator, also induced shedding of CD62L in B-CLL lymphocytes (25), which is why we also considered CD62L downregulation as a marker of B lymphocyte activation. Due to the unchanged  $\text{Ca}^{2+}$  flux upon thapsigargin treatment however, we hypothesize that the chronic B lymphocyte activation is an indirect effect of the R625X mutation in *CACNA1F*.

CRAC channel deficiencies do not impair T lymphocyte development but severely reduce proliferation and effector function due to strongly impaired SOCE (26–28). Thapsigargin treatment induced a lower  $\text{Ca}^{2+}$  influx into our patients' T lymphocytes than into those of healthy controls. Since thapsigargin skips other TCR/BCR-induced signaling pathways and directly induces SOCE, this reduction in  $\text{Ca}^{2+}$  mobilization demonstrates that, like the CRAC channel, Cav1.4 also contributes to SOCE. However, when stimulating T lymphocytes via the TCR using  $\alpha$ -CD3, the differences in  $\text{Ca}^{2+}$  flux were not observed. On the other hand, Jurkat T cells treated with Cav1.4 shRNA did show a marked reduction of  $\alpha$ -CD3-induced  $\text{Ca}^{2+}$  flux. Also, we have previously demonstrated that the L-type  $\text{Ca}^{2+}$  channel inhibitor nifedipine blocks a TCR-induced  $\text{Ca}^{2+}$  flux in Jurkat T cells as well as human PBMCs (14). We therefore hypothesize that the reason we did not observe a reduced TCR-induced  $\text{Ca}^{2+}$  flux in our patients may be that their T lymphocyte subset composition is different from the healthy controls we compare them to, as shown in **Fig. 1C**. Indeed, it has previously been demonstrated that CD45RO+ memory T cells exhibit a higher  $\alpha$ -CD3-mediated  $\text{Ca}^{2+}$  response than CD45RA+ naïve T lymphocytes (29). The higher frequency of central and effector memory T lymphocytes in our patients might therefore make up for the expected reduced  $\text{Ca}^{2+}$  flux when averaging the  $\text{Ca}^{2+}$  signal of naïve and memory T lymphocytes together. Thapsigargin simulation on the other hand, shows a reduced  $\text{Ca}^{2+}$  flux

even when comparing the mixed T lymphocyte populations, since it bypasses the proximal TCR signaling pathway where the different signaling strengths of naïve and memory T lymphocytes most likely manifest.

We have previously demonstrated that despite diminishing the  $\text{Ca}^{2+}$  flux nifedipine treatment also reduced the TCR-induced translocation of NFAT, activity of ERK1/2 as well as the secretion of IL-2 and the expression of the IL-2 receptor (14). The retained ability to secrete cytokines in our patient's T lymphocytes is not necessarily inappropriate for exhausted T lymphocytes; exhaustion does not yield lack of function and in human patients when studying non-antigen specific responses, it can be challenging to detect the altered function comparing to healthy controls. Studies have shown that the overexpression of IRs does not always correlate with decreased cytokine secretion capacity as often seen in exhaustion (30). Instead, the differentiation and activation status of the T lymphocytes is concomitant with the expression of IRs (30–33). However, previous clinical tests demonstrating diminished lymphocyte proliferation in response to antigenic as well as mitogenic stimuli (**Table S4**) do indeed suggest functional exhaustion of the patients' T cells.

Also in mice, Cav1.4-deficient T lymphocytes exhibited reduced thapsigargin-induced  $\text{Ca}^{2+}$  mobilization, as shown in previous work in our lab (13). In  $\beta 3$  KO CD4 T lymphocytes, CD3 crosslinking also led to a diminished  $\text{Ca}^{2+}$  flux but, conversely, thapsigargin-induced  $\text{Ca}^{2+}$  flux was normal (34). Despite these discrepancies, both KO mouse models displayed impaired nuclear translocation of NFAT, which resulted in reduced cytokine production (13,34,35).

The three siblings incur frequent recurrent ear- as well as upper respiratory tract infections. Previous clinical tests have shown that T lymphocyte proliferation of the patients is decreased in response to antigens and mitogens, which indeed suggests that Cav1.4-deficient lymphocytes (despite normal TCR-induced cytokine responses) cannot efficiently respond to pathogens and clear infections. In the patients, this would also provide an explanation for their phenotype: the recurrent infections lead to the increase in memory T lymphocyte frequency and upregulation of exhaustion markers as well as the expansion of regulatory T lymphocytes. Also, MAIT lymphocytes preoccupied with recognizing vitamin-B metabolites from bacteria and their expansion implies the patients had all experienced chronically bacterial infections. Because of these frequent infections, the B lymphocytes of the patients also remain in a chronic state of activation. Alternatively, the phenotype might also arise independent of an underlying infection and instead result from a lymphocyte development defect due to Cav1.4 deficiency. This is supported by the fact that the patients have not reported any infections immediately prior to our analysis and the same phenotype was found using samples drawn at two different time points (data only shown for one). Lastly, the increase of anti-nuclear antibodies that was found in the three brothers suggests that Cav1.4 deficiency also might have an impact on tolerance. Abnormal T lymphocytes selection would also provide another explanation for the upregulation of the different activation/exhaustion markers on T lymphocytes.

It is important to note that besides the many cases of CSNB that are caused by mutations in *CACNA1F*, a growing list of patients do complain about recurrent infections and therefore and seem to display the immune phenotype we observed. Several affected families reporting immune-related symptoms have self-founded a Facebook group

(<https://www.facebook.com/groups/883482391791546/>) in which they share their experiences of living with this gene defect. It is possible that a specific, potentially chronic infection triggered the disease in our patients. In many PIDs EBV as well as cytomegalovirus infections are reported to exacerbate the disease. An example for this is XLP disorder where an EBV infection leads to disease progression resulting in hyperproliferation of T lymphocytes and an aggravated cellular immune response. Interestingly, in previous clinical tests two of our patients (third patient not tested) were shown to have high levels of serum antibodies against EBV as well as high EBV viral loads (**Table S5**) and they reported that their symptoms worsened after mononucleosis during their teens. This deteriorating of a Cav1.4-related condition is also supported by a recent publication of our lab, which concludes that murine gamma herpesvirus 68, a viral ortholog of human EBV, can exacerbate the phenotype of a Cav1.4-deficient mouse model (36).

The severity of a phenotype in patients can also be affected by modifier genes. SNPs in modifier genes can alter phenotypes that are usually caused by a mutation in another gene, the so called target gene (37). This can affect the penetrance and expressivity of the target gene mutation. Modifier genes have been proposed to alter disease severity of night blindness of patient with a *CACNA1F* mutation (38). It is therefore plausible that modifier alleles also alter the immune phenotype caused by Cav1.4 deficiency and thereby change the penetrance and expressivity of the disease. An incomplete penetrance can also be observed in STIM1 deficiency where two cousins that, despite reduced SOCE and impaired NK effector functions, lack clinical symptoms (39). Lastly, following our original description of alternative splicing in Cav genes and the existence of spliceforms of Cav1.4 mRNA unique to T lymphocytes (12), at least nineteen, naturally occurring alternative splice variants of the native CaV1.4 mRNA were detected in the retina (40). It is

possible that specific mutations in *CACNA1F* may be spliced out resulting in partial phenotypes depending on the spliceforms that remain unaffected.

In conclusion, we have identified the first primary human immunodeficiency caused by a genetic mutation in any L-type  $\text{Ca}^{2+}$  channel. This mutation results in impaired  $\text{Ca}^{2+}$  signaling in T cells and causes T lymphocyte dysfunction as seen in chronic infections and cancer with exhaustion in the setting of chronic antigen exposure. These studies establish the importance of L-type  $\text{Ca}^{2+}$  channels to immune physiology in humans.

## Methods

Patient recruitment: CHOP: Patients were enrolled on a CHOP IRB approved protocol (PIs: Kathleen Sullivan or Neil Romberg). Penn: Patients were enrolled on a UPenn approved protocol (PI: Ramin Herati) or via the Human Immunology Core. UBC: Clinical Research Ethics Board granted approval for the human study (PI: Wilf Jefferies). Informed consent was obtained from all volunteers before whole-blood donation.

PBMC acquisition: for CyTOF and cytokine analysis: Venous blood was obtained by venipuncture and prepared for peripheral blood mononuclear cells (PBMCs) using the SepMate system (STEMCELL Technologies) which were cryopreserved until used for the following studies.

For lymphocyte population flow cytometry and  $\text{Ca}^{2+}$  flux: 10 ml of whole blood were collected into tubes containing sodium citrate (12 mM). PBMCs were then isolated using Lymphoprep (STEMCELL Technologies, cat. nr. 07801) according to protocol and used in subsequent experiment (lymphocyte population analysis) or frozen down in fetal bovine serum (FBS) with 10% DMSO (Thermo Fisher) for later use ( $\text{Ca}^{2+}$  flux).

Flow cytometry human lymphocyte population analysis: Freshly isolated or cryopreserved  $2 \times 10^6$  human PBMCs, resuspended in PBS with 2% FBS, were labelled for 30 minutes at 4°C in the dark with different antibody panels. The antibodies used were:  $\alpha$ -CD8 (RPA-T8, BioLegend, cat. nr. 301005),  $\alpha$ -CD4 (RPA-T4, BioLegend, cat. nr. 300511),  $\alpha$ -CD3 (UCHT1, BioLegend, cat. nr. 300427),  $\alpha$ -CD62L (DREG-56, BioLegend, cat. nr. 304841),  $\alpha$ -CD45RO (UCHL1, BioLegend, cat. nr. 304205),  $\alpha$ -PD-1 (EH12.2H7, BioLegend, cat. nr. 329915),  $\alpha$ -IL-7R (A019D5, BioLegend, cat. nr. 351317),  $\alpha$ -CD19 (HIB19, BioLegend, cat. nr. 302211),  $\alpha$ -PD-L1 (29E.2A3, BioLegend, cat. nr. 329717),  $\alpha$ -HLA-DR (L243, BioLegend, cat. nr. 307623),  $\alpha$ -CD32 (FUN-2, BioLegend,

cat. nr. 303205),  $\alpha$ -CD14 (63D3, BioLegend, cat. nr. 367111). The cells were then washed twice with PBS, resuspended in PBS with 2% FBS and data were acquired on an LSRII (BD Biosciences) and analysed with FlowJo v10 software (Treestar, Inc).

Mass cytometry (CyTOF): Reagents for mass cytometry were purchased or generated using MAXPAR kit (Fluidigm) to custom conjugate using isotope-loaded polymers. Mass cytometry antibodies in this study are shown in **Table S7**. Staining was performed as previously published (41). Single cell suspensions of PBMCs were thawed and incubated with 20 $\mu$ M Lanthanum-139 (Trace Sciences)-loaded maleimido-mono-amide-DOTA (Macrocylics) in PBS 10 minutes to allow live/dead cell discrimination. Cells were washed in staining buffer and then resuspended in master mix of surface antibodies, incubated for 30 minutes at room temperature and washed twice in staining buffer. Cells were then fixed and permeabilized using the FoxP3 staining buffer kit (eBioscience) and then washed twice with 1X Permeabilization Buffer (eBioscience). Cells were then stained intracellularly for 60 minutes at room temperature. Three more washes were performed in 1X Permeabilization Buffer before being fixed using 1.6% PFA (Electron Microscopy Sciences) solution with Iridium and Osmium overnight at 4 degrees Celsius. Cells were washed twice in PBS and once in dH2O prior to data acquisition on a CyTOF Helios (Fluidigm). We used bead-based normalization of CyTOF data using the Nolan lab scripts (<https://github.com/nolanlab/bead-normalization/releases>). FSC files were analyzed using FlowJo v10 (Treestar, Inc) and viSNE (Cytobank).

Flow cytometry for human cytokine analysis: Cells were stimulated with  $\alpha$ -CD3 (coated plates, OKT3) and  $\alpha$ -CD28/CD49d (soluble, L293, L25, BD Biosciences) for 4.5 hours, in the presence of brefeldin A (BD Biosciences) and monensin (BD Biosciences). Cells were then stained with

cell surface and intracellular antibodies for flow cytometry. Flow cytometry antibodies in this study are shown in **Table S8**.

**Ca<sup>2+</sup> flux with human PBMCs:** Frozen 4 x 10<sup>6</sup> human PBMCs were thawed, resuspended in HBSS with 2% FBS, and labelled with 1 µM Fluo-4, 2 µM Fura Red (Thermo Fisher, cat. nr. F14201, F3021) for 45 minutes at room temperature in the dark. Cells were then washed, stained with α-CD19 (HIB19, BioLegend, cat. nr. 302211), α-CD8 (RPA-T8, BioLegend, cat. nr. 301026), α-CD4 (RPA-T4, BioLegend, cat. nr. 300511) for 30 minutes on ice, washed again, and resuspended in HBSS with 2% FBS. After prewarming the cells for 15 minutes at 37°C, baseline Ca<sup>2+</sup> levels were acquired for 30 seconds by flow cytometry. 1 µM thapsigargin (Thermo Fisher, cat. nr. T7458) was then added to the cells and acquisition was continued for a total of 5 minutes. Data were acquired on an LSRII (BD Biosciences) and analysed with FlowJo v9 software (Treestar, Inc).

**shRNA transfection of Jurkat T cells:** pGFP-V-RS vector (OriGene Technologies) expressing shRNA targeting human *CACNA1F* gene or pGFP-V-RS vector with scrambled shRNA cassette (control) was transfected into Jurkat T cells by Neon electroporation system (Invitrogen) according to manufacturer's guidelines. shRNA targeting sequence for CACNA1F is CCTGCACATAGTGCTCAATTCCATCATGA. Knockdown efficiency of the CACNA1F gene expression was determined by RT-PCR.

**Ca<sup>2+</sup> flux with Jurkat T cells:** 10<sup>6</sup> transfected (scrambled or Cav1.4 shRNA) Jurkat T cells were resuspended in HBSS with 2% FBS, and labelled with 1 µM Fluo-4, 2 µM Fura Red (Thermo Fisher, cat. nr. F14201, F3021) for 45 minutes at room temperature in the dark. Cells were then washed and again resuspended in HBSS with 2% FBS. After prewarming the cells for 15 minutes

at 37°C, baseline Ca<sup>2+</sup> levels were acquired for 30 seconds by flow cytometry.  $\alpha$ -CD3 (1:1000 dilution, HIT3a, Invitrogen) was then added to the cells and acquisition was continued for a total of 10 minutes. Data were acquired on an LSRII (BD Biosciences) and analysed with FlowJo v9 software (Treestar, Inc).

Exome Sequencing by GeneDX: Using genomic DNA from specimen of the three siblings and their mother, the Agilent Clinical Research Exome kit was used to target the exonic regions and flanking splice junctions of the genome. These targeted regions were sequenced simultaneously by massively parallel (NextGen) sequencing on an Illumina HiSeq sequencing system with 100bp paired-end reads. Bi-directional sequence was assembled, aligned to reference gene sequences based on human genome build GRCh37/UCSC hg19, and analysed for sequence variants using a custom-developed analysis tool (Xome Analyzer, GeneDx, Gaithersburg, MD, USA). Capillary sequencing or another appropriate method was used to confirm all potentially pathogenic variants identified in the siblings and their parents. Sequence alterations were reported according to the Human Genome Variation Society (HGVS) nomenclature guidelines. The exome was covered at a mean depth of 138x, with a quality threshold of 93.7%.

Sample size estimation: Sample size of the patient group was limited to three as we were unable to recruit more patients with a *CACNA1F* mutation for this study. The sample size of the control group was estimated to detect a Cohen's effect size of  $d = 2$  with a significance level of  $\alpha = 0.05$  and power of 75%. This results into a sample size of  $n \approx 8.1$  for the control group and was calculated using R's `pwr.t2n.test()` function.

Statistical tests: Statistical significance was determined with 2-sided unpaired Student's t tests using R's `t.test()` function. Technical replicates are from the same blood sample but different aliquots (either freshly isolated or cryopreserved PBMCs), analyzed on different days.

**Boxplots:** Points represent the individual data measurements. The center line in the boxplot is the median while the box represents the interquartile range (IQR). The upper and lower limits of the box represent the first (Q1) and the third quartile (Q3). The upper whisker limit is the max value  $< (Q3 + 1.5 * \text{IQR})$ . The lower whisker limit is the min value  $> (Q1 - 1.5 * \text{IQR})$ . Points that lie outside the whiskers range are outliers.

**Data Sharing Statement:** For original data, please contact [wilf@msl.ubc.ca](mailto:wilf@msl.ubc.ca).

### **Authorship Contributions:**

Conceived of the Study: WAJ

Designed research: FF, SRS, CGP, SEH, KES, WAJ

Performed research: FF, SRS, CJL, SEH, OK, KCOB, KM, MR, RSH, NDR, EJW, KES,

Analyzed data: all authors

Wrote paper: FF, WAJ

Edited paper: all authors

**Acknowledgments:** We would like to thank the patients and their family for their willingness to participate in this study. We thank Woosuk S. Hur and Dr. Christian Kastrup for providing healthy control blood samples. We also thank our sponsors for their funding for this work: F.F. was the recipient of a DOC Fellowship of the Austrian Academy of Science and the Dmitry Apel Memorial Scholarship; S.R.S. was the recipient of a John Richard Turner Fellowship; H.A. was the recipient of a Centre for Blood Research Graduate Student Award; W.A.J. was supported by grants from

the Canadian Institutes of Health Research (IPR-139079; MOP-102698), and a grant from Pascal Biosciences, Inc.; . E.J.W. was supported by the Parker Institute for Cancer Immunotherapy.


## References:

1. Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. *J Clin Immunol*. 2018 Jan;38(1):129–43.
2. Picard C, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. *Journal of Clinical Immunology*. 2015 Nov;35(8):696–726.
3. Smith-Garvin JE, Koretzky GA, Jordan MS. T Cell Activation. *Annual Review of Immunology*. 2009 Apr;27(1):591–619.
4. Nohara LL, Stanwood SR, Omilusik KD, Jefferies WA. Tweeters, Woofers and Horns: The Complex Orchestration of Calcium Currents in T Lymphocytes. *Frontiers in Immunology* [Internet]. 2015 May 21 [cited 2017 Dec 30];6. Available from: <http://journal.frontiersin.org/Article/10.3389/fimmu.2015.00234/abstract>
5. Omilusik KD, Nohara LL, Stanwood S, Jefferies WA. Weft, Warp, and Weave: The Intricate Tapestry of Calcium Channels Regulating T Lymphocyte Function. *Frontiers in Immunology* [Internet]. 2013 [cited 2017 Dec 30];4. Available from: <http://journal.frontiersin.org/article/10.3389/fimmu.2013.00164/abstract>
6. Feske S, Gwack Y, Prakriya M, Srikanth S, Poppel S-H, Tanasa B, et al. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. *Nature*. 2006 May 11;441(7090):179–85.
7. McCarl C-A, Picard C, Khalil S, Kawasaki T, Röther J, Papolos A, et al. ORAI1 deficiency and lack of store-operated Ca<sup>2+</sup> entry cause immunodeficiency, myopathy, and ectodermal dysplasia. *Journal of Allergy and Clinical Immunology*. 2009 Dec;124(6):1311–1318.e7.
8. Picard C, McCarl C-A, Papolos A, Khalil S, Lüthy K, Hivroz C, et al. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. *N Engl J Med*. 2009 May 7;360(19):1971–80.
9. Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A. Gene regulation mediated by calcium signals in T lymphocytes. *Nature Immunology*. 2001 Apr;2(4):316–24.
10. Fenninger F, Jefferies WA. What's Bred in the Bone: Calcium Channels in Lymphocytes. *The Journal of Immunology*. 2019 Feb 15;202(4):1021–30.
11. Badou A, Jha MK, Matza D, Flavell RA. Emerging Roles of L-Type Voltage-Gated and Other Calcium Channels in T Lymphocytes. *Frontiers in Immunology* [Internet]. 2013 [cited 2017 Dec 30];4. Available from: <http://journal.frontiersin.org/article/10.3389/fimmu.2013.00243/abstract>
12. Kotturi M, Jefferies W. Molecular characterization of L-type calcium channel splice variants expressed in human T lymphocytes. *Molecular Immunology*. 2005 Aug;42(12):1461–74.
13. Omilusik K, Priatel JJ, Chen X, Wang YT, Xu H, Choi KB, et al. The CaV1.4 Calcium Channel Is a Critical Regulator of T Cell Receptor Signaling and Naive T Cell Homeostasis. *Immunity*. 2011 Sep;35(3):349–60.
14. Kotturi MF, Carlow DA, Lee JC, Ziltener HJ, Jefferies WA. Identification and Functional Characterization of Voltage-dependent Calcium Channels in T Lymphocytes. *Journal of Biological Chemistry*. 2003 Nov 21;278(47):46949–60.

15. Mansergh F, Orton NC, Vessey JP, Lalonde MR, Stell WK, Tremblay F, et al. Mutation of the calcium channel gene *Cacna1f* disrupts calcium signaling, synaptic transmission and cellular organization in mouse retina. *Hum Mol Genet*. 2005 Oct 15;14(20):3035–46.
16. Boycott KM, Maybaum TA, Naylor MJ, Weleber RG, Robitaille J, Miyake Y, et al. A summary of 20 *CACNA1F* mutations identified in 36 families with incomplete X-linked congenital stationary night blindness, and characterization of splice variants. *Hum Genet*. 2001 Feb;108(2):91–7.
17. Golubovskaya V, Wu L. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy. *Cancers*. 2016 Mar 15;8(12):36.
18. Sallusto F, Geginat J, Lanzavecchia A. Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance. *Annual Review of Immunology*. 2004 Apr;22(1):745–63.
19. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. *Nature Reviews Immunology*. 2015 Aug;15(8):486–99.
20. Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson MA, Michaëlsson J, et al. T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection. Luban J, editor. *PLoS Pathogens*. 2014 Jul 17;10(7):e1004251.
21. Pauken KE, Wherry EJ. SnapShot: T Cell Exhaustion. *Cell*. 2015 Nov;163(4):1038-1038.e1.
22. Crotty S. A brief history of T cell help to B cells. *Nature Reviews Immunology*. 2015 Mar;15(3):185–9.
23. Chen RWS, Greenberg JP, Lazow MA, Ramachandran R, Lima LH, Hwang JC, et al. Autofluorescence Imaging and Spectral-Domain Optical Coherence Tomography in Incomplete Congenital Stationary Night Blindness and Comparison With Retinitis Pigmentosa. *American Journal of Ophthalmology*. 2012 Jan;153(1):143-154.e2.
24. Sengstake S, Boneberg E-M, Illges H. CD21 and CD62L shedding are both inducible via P2X7Rs. *International Immunology*. 2006 Jul;18(7):1171–8.
25. Gu B, Bendall LJ, Wiley JS. Adenosine triphosphate-induced shedding of CD23 and L-selectin (CD62L) from lymphocytes is mediated by the same receptor but different metalloproteases. *Blood*. 1998 Aug 1;92(3):946–51.
26. Partisani M, Le Deist F, Hivroz C, Fischer A, Korn H, Choquet D. The calcium current activated by T cell receptor and store depletion in human lymphocytes is absent in a primary immunodeficiency. *J Biol Chem*. 1994 Dec 23;269(51):32327–35.
27. Le Deist F, Hivroz C, Partisani M, Thomas C, Buc HA, Oleastro M, et al. A primary T-cell immunodeficiency associated with defective transmembrane calcium influx. *Blood*. 1995 Feb 15;85(4):1053–62.
28. Feske S, Müller JM, Graf D, Kroczeck RA, Dräger R, Niemeyer C, et al. Severe combined immunodeficiency due to defective binding of the nuclear factor of activated T cells in T lymphocytes of two male siblings. *Eur J Immunol*. 1996 Sep;26(9):2119–26.
29. Robinson AT, Miller N, Alexander DR. CD3 antigen-mediated calcium signals and protein kinase C activation are higher in CD45R0+ than in CD45RA+ human T lymphocyte subsets. *European Journal of Immunology*. 1993 Jan;23(1):61–8.
30. Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory Receptors Beyond T Cell Exhaustion. *Frontiers in Immunology* [Internet]. 2015 Jun 26 [cited 2018 Jul 5];6. Available from: <http://journal.frontiersin.org/Article/10.3389/fimmu.2015.00310/abstract>


31. Baitsch L, Legat A, Barba L, Fuertes Marraco SA, Rivals J-P, Baumgaertner P, et al. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. *PLoS ONE*. 2012;7(2):e30852.
32. Duraiswamy J, Ibegbu CC, Masopust D, Miller JD, Araki K, Doho GH, et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. *J Immunol*. 2011 Apr 1;186(7):4200–12.
33. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than ‘Exhaustion’ of Human CD8 T Cells. *Front Immunol*. 2013;4:455.
34. Badou A, Jha MK, Matza D, Mehal WZ, Freichel M, Flockerzi V, et al. Critical role for the beta regulatory subunits of Cav channels in T lymphocyte function. *Proc Natl Acad Sci USA*. 2006 Oct 17;103(42):15529–34.
35. Jha MK, Badou A, Meissner M, McRory JE, Freichel M, Flockerzi V, et al. Defective survival of naive CD8+ T lymphocytes in the absence of the beta3 regulatory subunit of voltage-gated calcium channels. *Nat Immunol*. 2009 Dec;10(12):1275–82.
36. Fenninger F, Han J, Stanwood SR, Nohara LL, Arora H, Choi KB, et al. Mutation of an L-Type Calcium Channel Gene Leads to T Lymphocyte Dysfunction. *Front Immunol*. 2019 Oct 29;10:2473.
37. Riordan JD, Nadeau JH. From Peas to Disease: Modifier Genes, Network Resilience, and the Genetics of Health. *The American Journal of Human Genetics*. 2017 Aug;101(2):177–91.
38. Men CJ, Bujakowska KM, Comander J, Place E, Bedoukian EC, Zhu X, et al. The importance of genetic testing as demonstrated by two cases of CACNA1F-associated retinal generation misdiagnosed as LCA. *Mol Vis*. 2017;23:695–706.
39. Parry DA, Holmes TD, Gamper N, El-Sayed W, Hettiarachchi NT, Ahmed M, et al. A homozygous STIM1 mutation impairs store-operated calcium entry and natural killer cell effector function without clinical immunodeficiency. *Journal of Allergy and Clinical Immunology*. 2016 Mar;137(3):955–957.e8.
40. Tan GMY, Yu D, Wang J, Soong TW. Alternative Splicing at C Terminus of Ca  $\nu$  1.4 Calcium Channel Modulates Calcium-dependent Inactivation, Activation Potential, and Current Density. *Journal of Biological Chemistry*. 2012 Jan 6;287(2):832–47.
41. B. Bengsch *et al.*, Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. *Immunity*. **48**, 1029–1045.e5 (2018).

**Figures:**




**Fig. 1. CACNA1F transmembrane protein cartoon and family pedigree of the three affected siblings**

Cartoon depicting the structure of the  $\alpha 1$  subunit of Cav1.4 and the location of the R625X mutation (A). The mother of the siblings is a confirmed carrier of the R625X mutation and other individuals on the maternal side of the family are assumed carriers of the allele. While the two affected (assumed) males display CSNB, the female carriers (assumed) exhibit autoimmune defects (B).



**Fig. 2. Cav1.4-deficient patients have a reduced number of CD4 T cells and an increased frequency of memory T cells**

PBMCs of patients (n=3) and healthy controls (n=9) were stained with different antibodies and analyzed by flow cytometry. Frequencies of CD4+, CD8+, CD4-CD8- and CD19+ lymphocytes are shown (A). Gating strategy is shown (B). The different population frequencies shown in boxplots are classified as CD62L+ CD45RO- (naïve), CD62L+ CD45RO+ (T<sub>CM</sub>), CD62L- CD45RO+ (T<sub>EM</sub>), CD62L- CD45RO- (end-stage T<sub>Eff</sub>) (C). Representative of two technical replicates. \*p<0.05 \*\* p<0.01.




**Fig. 3. Cav1.4-deficient T cells show signs of exhaustion. B lymphocytes are chronically activated.**

PBMCs of patients (n=3) and healthy controls (n=9) were stained with different antibodies and analyzed by flow cytometry (A,C) / CyTOF (B). The PD-1+ frequency is shown in boxplots for the indicated populations, which are classified as CD62L+ CD45RO- (naïve), CD62L+ CD45RO+ (T<sub>CM</sub>), CD62L- CD45RO+ (T<sub>EM</sub>), CD62L- CD45RO- (end-stage T<sub>eff</sub>) (A). Frequencies of CD8 T lymphocytes exhibiting other exhaustion markers are shown (B). The population quantified/shown

in (C) is gated on B lymphocytes only (CD19+). Representative of two technical replicates (A,C).

Experiment done once (B). Histograms show one representative sample of each genotype. \*


p<0.05 \*\* p<0.01 \*\*\* p<0.001 \*\*\*\* p<0.0001.



**Fig. 4. Cav1.4-deficient T lymphocytes exhibit a reduced  $\text{Ca}^{2+}$  flux**


PBMCs of patients (n=3) and healthy controls (n=8) were stained with  $\text{Ca}^{2+}$  dyes and different T and B lymphocyte-specific antibodies and analyzed by flow cytometry. Thapsigargin was added to cells after 30 seconds of acquisition. The boxplots show the quantified slopes of increasing  $\text{Ca}^{2+}$  concentration for each cell type (A). The flow cytometry kinetics plots show the actual  $\text{Ca}^{2+}$  influx over time (B). Representative of two technical replicates. \* p<0.05.

## Supplementary Materials:




**Fig. S1.**

PBMCs of patients (n=3) and healthy controls (n=9) were stained with different antibodies and analyzed by CyTOF. This experiment was only done once.



**Fig. S2. Cav1.4 shRNA treated Jurkat T cells exhibit a reduced TCR-induced  $\text{Ca}^{2+}$  flux.**

(A) Cav1.4 gene expression by qRT-PCR in Jurkat cells after 48 hours of Cav1.4 shRNA transfection. (B) Jurkat T cells, transfected with either Cav1.4 shRNA or scrambled control shRNA were loaded with  $\text{Ca}^{2+}$  dyes and analyzed by flow cytometry. After 30 seconds the cells were activated with  $\alpha$ -CD3. Knockdown was performed once,  $\text{Ca}^{2+}$  flux experiment is a representative of two technical replicates.



**Fig. S3. T lymphocyte activation marker CD38 is increased, while cytokine secretion is unchanged in Cav1.4-deficient patients upon stimulation.**

PBMCs of patients (n=3) and healthy donors (n=4) were stimulated with  $\alpha$ -CD3 and  $\alpha$ -CD28/49d for 4.5 hours and subsequently stained with various antibodies for extracellular markers and intracellular cytokines. The frequencies of CD38+, IFN $\gamma$ +, and IL-2+ lymphocytes are shown for CD4 and CD8 non-naïve T lymphocytes, which are classified as NOT CD27+ CD45RA+. This experiment was only done once.

	<b>Patient 1</b>	<b>Patient 2</b>	<b>Patient 3</b>
<b>Lab tests</b>			
Impaired lymphocyte proliferation in response to antigens and mitogens	X	X	
Polycythemia	X	X	X
<b>Skin conditions</b>			
Rash - dermatomyositis pattern			X
Rashes - Urticaria	X		
Dermatographism	X		
<b>Eye disorders</b>			
Optic atrophy	X	X	X
Congenital stationary night blindness	X	X	X
Dry Eye Syndrome			X
Keratitis			X
Blepharitis			X
Conjunctivitis			X
<b>Muscle / joint disorders</b>			
Myalgia	X		X
Arthralgia	X		X
Muscle cramps			X
Bilateral knee joint effusions			X
Muscle weakness	X		
<b>Ear, nose, and throat disorders</b>			
Chronic ear infections			X
Chronic rhinitis	X		
Reoccurring pharyngitis	X		
Sinusitis		X	
<b>Infections</b>			
Pneumonia	X	X	X
Frequent viral infections	X	X	X
Recurring EBV		X	X
<b>Other features</b>			
Bilateral hydroceles			X
Torsion of the appendix testis			X
Testicular pain	X		
Gastroesophageal junction polyps			X
Gastritis	X	X	X
Intussusception		X	
Aphthous ulcers	X	X	X
Fatigue and malaise	X	X	X

Undifferentiated connective tissue disease			X
Kidney stones			X
Raynauds phenomenon	X		
Ehlers Danlos syndrome	X		
Mild persistent asthma	X		
Numbness and tingling hands	X		
Rib lesion	X		
Frequent fevers		X	

**Table S1. Clinical history of patients.**

	Patient 1 & 2 Ref Range & Units	Patient 1	Patient 2	Patient 3 Ref Range & Units	Patient 3
WBC	3.8 - 9.8 K/ul	6.2	4.7	3.9 - 8.8 K/ul	6.0
RBC	4.50 - 5.30 M/ul	4.68	<b>5.37 (H)</b>	4.50 - 5.90 M/ul	5.58
HGB	13.0 - 16.0 g/dl	13.9	15.4	13.5 - 17.5 g/dl	16.4
HCT	37.0 - 49.0 %	42.1	45.1	41.0 - 53.0 %	47.4
MCV	78.0 - 98.0 fl	90.0	84.0	80.0 - 100.0 fl	84.9
MCH	26.0 - 34.0 pg	29.7	28.7	26.0 - 34.0 pg	29.4
MCHC	31.0 - 37.0 g/dl	33.0	34.1	31.0 - 37.0 g/dl	34.6
RDW with Standard Deviation	36.7 - 43.8 fl	41.7	39.1	37.8 - 46.1 fl	37.9
RDW Coefficient of Variation	12.4 - 14.5 %	12.7	12.8	12.3 - 14.3 %	12.3
Platelet Count	150 - 400 K/uL	237	225	150 - 400 K/uL	161
MPV	9.6 - 11.8 fl	11.0	10.7	9.7 - 11.9 fl	11.2
Immature Granulocyte	0.0 - 0.3 %	0.2	0.2	0.0 - 0.6 %	0.3
Neutrophils	32.5 - 74.7 %	65.0	43.5	40.3 - 74.8 %	62.0
Lymphocytes	16.4 - 52.7 %	26.0	42.2	12.2 - 47.1 %	27.3
Monocytes	4.4 - 12.3 %	7.5	8.4	4.4 - 12.3 %	7.5
Eosinophils	0.0 - 4.0 %	0.8	<b>4.9 (H)</b>	0.0 - 4.4 %	2.2
Basophils	0.0 - 0.7 %	0.5	<b>0.8 (H)</b>	0.0 - 0.7 %	0.7
Absolute Immature Granulocyte	0 - 30 /ul	10	10	0 - 90 /ul	20
Absolute Neutrophils	1540 - 7040 /ul	4000	2060	1820 - 7420 /ul	3730
Absolute Lymphocytes	970 - 3260 /ul	1600	2000	850 - 3000 /ul	1640
Absolute Monocytes	180 - 780 /ul	460	400	190 - 770 /ul	450
Absolute Eosinophils	40 - 380 /ul	50	230	30 - 440 /ul	130
Absolute Basophils	10 - 50 /ul	30	40	10 - 50 /ul	40
Differential Method		Automated	Automated		Automated

Table S2. Complete blood count with differential of siblings.

	Patient 1 Ref Range & Units	Patient 1	Patient 2 Ref Range & Units	Patient 2	Patient 3 Ref Range & Units	Patient 3
CD3+	55 - 83 %	71.0	52 - 78 %	67.8	55 - 83 %	67.3
CD3+ Absolute	700 - 2100 cells/µl	1136	800 - 3500 cells/µl	1356	700 - 2100 cells/µl	1104
CD3+/CD4+	28 - 57 %	28.2	25 - 48 %	33.8	28 - 57 %	34.7
CD3+/CD4+ Absolute	300 -1400 cells/µl	451	400 - 2100 cells/µl	676	300 -1400 cells/µl	569
CD3+/CD8+	10 - 39 %	32.6	9 - 35 %	29.1	10 - 39 %	26.4
CD3+/CD8+ Absolute	200 - 900 cells/µl	522	200 - 1200 cells/µl	582	200 - 900 cells/µl	433
CD19+	6 - 19 %	15.7	8 - 24 %	14.5	6 - 19 %	13.3
CD19+ Absolute	100 - 500 cells/µl	251	200 - 3500 cells/µl	290	100 - 500 cells/µl	218
CD20+	3.1 - 21.5 %	15.5	3.1 -21.5 %	14.3	3.1 - 21.5 %	13.2
CD20+ Absolute	0 - 479 cells/µl	248	0 - 479 cells/µl	286	0 - 479 cells/µl	216
CD3-/CD16(B73.1)+ and/or CD56+	7 - 31 %	11.9	6 - 27 %	17.3	7 - 31 %	19.3
CD3-/CD16(B73.1)+ and/or CD56+ Abs	90 - 600 cells/µl	190	70 - 1200 cells/µl	346	90 - 600 cells/µl	317
CD4+/CD45RA+	12.5 - 42.2 %	<b>9.8 (L)</b>	12.5 - 42.2 %	13.0	12.5 - 42.2 %	<b>11.7 (L)</b>
CD4+/CD45RA+ Absolute	41 - 1121 cells/µl	157	41 - 1121 cells/µl	260	41 - 1121 cells/µl	192
CD4+/CD45R0+	10.1 - 27.9 %	18.2	10.1 - 27.9 %	19.2	10.1 - 27.9 %	22.6
CD4+/CD45R0+ Absolute	153 - 582 cells/µl	291	153 - 582 cells/µl	384	153 - 582 cells/µl	371
CD4+/CD8+ Ratio	1 - 3.6	<b>0.9 (L)</b>	0.9 - 3.4	1.2	1 - 3.6	1.3

**Table S3. B-T NK panel of siblings**

	Patient 1		Patient 2		Patient 3	
	CPM	SI	CPM	SI	CPM	SI
Antigen background	86		227		4745	
Tetanus	5070	59	9215	41	32298	7
Candida	3616	42	6056	27	14139	3
Mitogen background	172		266		395	
PWM	20233	118	20210	76	81204	206
ConA	54679	318	53397	201	100903	255
PHA	62156	361	64221	241	171802	435
		Control of Patient 1		Control of Patient 2		Control of Patient 3
		CPM	SI	CPM	SI	CPM
Antigen background	553		553		799	
Tetanus	15309	28	15309	28	27475	34
Candida	12932	23	12932	23	28674	36
Mitogen background	299		299		556	
PWM	51001	171	51001	171	72116	130
ConA	60878	204	60878	204	130355	234
PHA	77314	259	77314	259	186396	336

**Table S4. Clinical test of lymphocyte proliferation in response to antigens/mitogens**

	Patient 2	Patient 3	Negative reference range
<b>EBV antibody detection</b>	U/ml	U/ml	U/ml
early antigen IgG	18.1	14.7	0.0 - 8.9
nuclear antigen IgG	160	339	0.0 - 17.9
VCA IgG	85.1	519	0.0 - 17.9
VCA IgM	<36.0	<36.0	0.0 - 35.9
<b>EBV quantitative PCR</b>	-	-	-
viral load, blood	350	n/a	<125
log value, blood	2.54	n/a	<2.1
viral load, lymphs	n/a	83	<50
viral load, plasma	n/a	581	<50
log value, lymphs	n/a	1.92	<1.7
log value, plasma	n/a	2.76	<1.7

**Table S5. EBV viral loads and EBV antibodies in two of the three siblings**

Gene	Variant	dbSNP	Patient 1	Patient 2	Patient 3	Mother
<b>Pathogenic variants</b>						
CACNA1F	p.R625X	rs886039559	-/0	-/0	-/0	-/+
<b>Benign and likely benign variants</b>						
SH2D1A	p.V40M	rs199639961	+/0	-/0	+/0	-/+
AMPD	p.Q45X	rs17602729	-/-	+/+	-/+	-/+
AMPD	p.P81L	rs61752479	-/-	+/+	-/+	-/+
MEFV	p.G138G	rs224224	+/+	-/+	-/+	N/A
MEFV	p.A165A	rs224223	+/+	-/+	-/+	N/A
MEFV	p.D102D	rs224225	+/+	-/+	-/+	N/A
MEFV	p.R314R	rs224213	-/-	-/+	-/+	N/A
MEFV	p.E474E	rs224208	-/-	-/+	-/+	N/A
MEFV	p.Q476Q	rs224207	-/-	-/+	-/+	N/A
MEFV	p.D510D	rs224206	-/-	-/+	-/+	N/A
MEFV	p.P588P	rs1231122	-/-	-/+	-/+	N/A
NLRP3	p.A244A	rs3806268	-/-	-/-	-/-	N/A
TNFRSF1A	p.P12P	rs767455	-/-	-/+	-/+	N/A
TNFRSF1A	c.625+10	rs1800693	-/-	-/+	-/+	N/A
TNFRSF1A	c.740-9	rs12426675	+/-	-/+	-/+	N/A
<b>Genes reviewed for secondary findings</b>						
ACTA2			+/-	+/-	+/-	N/A
ACTC1			+/-	+/-	+/-	N/A
APC			+/-	+/-	+/-	N/A
APOB			+/-	+/-	+/-	N/A
BRCA1			+/-	+/-	+/-	N/A
BRCA2			+/-	+/-	+/-	N/A
CACNA1S			+/-	+/-	+/-	N/A
COL3A1			+/-	+/-	+/-	N/A
DSC2			+/-	+/-	+/-	N/A
DSG2			+/-	+/-	+/-	N/A
DSP			+/-	+/-	+/-	N/A
FBN1			+/-	+/-	+/-	N/A
GLA			+/-	+/-	+/-	N/A
KCNH2			+/-	+/-	+/-	N/A
KCNQ1			+/-	+/-	+/-	N/A
LDLR			+/-	+/-	+/-	N/A
LMNA			+/-	+/-	+/-	N/A
MEN1			+/-	+/-	+/-	N/A
MLH1			+/-	+/-	+/-	N/A
MSH2			+/-	+/-	+/-	N/A
MSH6			+/-	+/-	+/-	N/A

MUTYH			+/+	+/+	+/+	N/A
MYBPC3			+/+	+/+	+/+	N/A
MYL2			+/+	+/+	+/+	N/A
MYL3			+/+	+/+	+/+	N/A
MYLK			+/+	+/+	+/+	N/A
MYH7			+/+	+/+	+/+	N/A
MYH11			+/+	+/+	+/+	N/A
NF2			+/+	+/+	+/+	N/A
PCSK9			+/+	+/+	+/+	N/A
PKP2			+/+	+/+	+/+	N/A
PMS2			+/+	+/+	+/+	N/A
PRKAG2			+/+	+/+	+/+	N/A
PTEN			+/+	+/+	+/+	N/A
RB1			+/+	+/+	+/+	N/A
RET			+/+	+/+	+/+	N/A
RYR1			+/+	+/+	+/+	N/A
RYR2			+/+	+/+	+/+	N/A
SCN5A			+/+	+/+	+/+	N/A
SDHAF2			+/+	+/+	+/+	N/A
SDHB			+/+	+/+	+/+	N/A
SDHC			+/+	+/+	+/+	N/A
SDHD			+/+	+/+	+/+	N/A
SMAD3			+/+	+/+	+/+	N/A
STK11			+/+	+/+	+/+	N/A
TGFBR1			+/+	+/+	+/+	N/A
TGFBR2			+/+	+/+	+/+	N/A
TMEM43			+/+	+/+	+/+	N/A
TNNI3			+/+	+/+	+/+	N/A
TNNT2			+/+	+/+	+/+	N/A
TP53			+/+	+/+	+/+	N/A
TPM1			+/+	+/+	+/+	N/A
TSC1			+/+	+/+	+/+	N/A
TSC2			+/+	+/+	+/+	N/A
VHL			+/+	+/+	+/+	N/A
WT1			+/+	+/+	+/+	N/A

**Table S6. Summary of known genetic variants in the patients and their mother**

+/+ normal homozygous, -/- mutant homozygous, -/+ mutant heterozygous,

+/- normal hemizygous, -/-0 mutant hemizygous

Metal	Antibody	Purchased conjugated/ Conjugated in lab	Clone	Source	Order #
89Y	CD45	Purchased	HI30	Fluidigm	3089003B
113 In	CD45RO	Conjugated	UCHL1	BD	555491
115 In	CD123	Conjugated	6H6	BioLegend	306002
141 Pr	CD3	Conjugated	UCHT1	BioLegend	300443
142 Nd	CD26	Conjugated	BA 5b	BioLegend	302702
143 Nd	CD4	Conjugated	RPA-T4	BioLegend	300502
144 Nd	CD11b	Purchased	ICRF44	Fluidigm	3144001B
145 Nd	CD19	Conjugated	HIB19	BioLegend	302202
146 Nd	CD8	Conjugated	RPA-T8	BioLegend	301002
147 Sm	CD14	Conjugated	M5E2	BioLegend	301810
148 Nd	CD56	Conjugated	HCD56	BioLegend	318345
149 Sm	CD11c	Conjugated	3.9	Tonbo	70-0116-U100
150 Nd	FceRI	Purchased	AER-37 (CRA-1)	Fluidigm	3150027B
151 Eu	CD39	Conjugated	A1	BioLegend	328202
152 Sm	Granzyme B	Conjugated	CLB-GB11	Thermo Fisher	MA1-10338
153 Eu	CD45RA	Purchased	HI100	Fluidigm	3153001B
154 Sm	NKp46	Conjugated	9E2	BioLegend	331904
155 Gd	CD27	Purchased	L128	Fluidigm	3155001B
156 Gd	Helios	Conjugated	22F6	BioLegend	137202
158 Gd	PD-1	Conjugated	EH12.2H7	BioLegend	329902
159 Tb	CCR7	Purchased	G043H7	Fluidigm	3159003A
160 Gd	Tbet	Purchased	4B10	Fluidigm	3160010B
161 Dy	CTLA-4	Purchased	14-D3	Fluidigm	3161004B
162 Dy	Foxp3	Purchased	PCH101	Fluidigm	3162011A
163 Dy	CRTH2	Purchased	BM16	Fluidigm	3163003B
164 Dy	CD161	Purchased	HP-3G10	Fluidigm	3164009B
165 Ho	Eomes	Conjugated	WD1928	Invitrogen	14-4877-82
166 Er	TCF-1	Conjugated	7F11A10	BioLegend	655202
167 Er	CD38	Purchased	HIT2	DVS	3167001B
168 Er	CD138	Purchased	DL-101	Fluidigm	3168009B
169 Tm	TIGIT	Conjugated	MBSA43	Invitrogen	16-9500-82
170 Er	CXCR5	Conjugated	RF8B2	BD	552032
171 Yb	ST2	Conjugated	B4E6	MD Biosciences	101002
172 Yb	Ki67	Purchased	B56	Fluidigm	3172024B
173 Yb	HLA-DR	Purchased	L243	Fluidigm	3173005B
174 Yb	TCRgd	Conjugated	B1	BioLegend	331202

175 Lu	IgD	Conjugated	IA6-2	BioLegend	348235
176 Yb	CD127	Purchased	A019D5	Fluidigm	3176004B
209 Bi	CD16	Purchased	3G8	Fluidigm	3209002B

**Table S7. Mass cytometry (CyTOF) human panel**

Fluorochrome	Antibody	Clone	Source	Order #
BV421	IL-2	5344.111	BD	562914
V500	CD14	M5E2	BD	561391
V500	CD16	3G8	BD	561394
V500	CD19	HIB19	BD	561121
Aqua	Live/Dead		Invitrogen	L34966
QD585	CD3	OKT3	BioLegend	317304
BV605	CD45RA	HI100	BioLegend	304134
SB645	CD8	RPA-T8	Invitrogen	64-0088-42
BV711	CD279/PD-1	EH12.1	BD	564017
BV785	CD27	O323	BioLegend	302831
AF647	IL-21	3A3-N2	BioLegend	513006
AF700	Foxp3	PCH101	Invitrogen	56-4776-41
APC/Cy7	IL-17A	BL168	BioLegend	512319
AF488	IL-10	JES3-9D7	BioLegend	501411
PE	IL-13	JES10-5A2	BioLegend	501903
PE-TxRd	CD38	HIT2	Life	MHCD3817
PE-Cy5.5	CD4	SK3	eBio	35-0047-42
PE/Cy7	IFNg	B27	BioLegend	506518

**Table S8. Flow cytometry human cytokine panel**